Video

Dr. Desai on the Ideal Patient for Bladder Preservation in Urothelial Cancer

Author(s):

Neil Desai, MD, discusses the ideal patient for bladder preservation in urothelial cancer.

Neil Desai, MD, associate professor, radiation oncology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center, discusses the ideal patient for bladder preservation in urothelial cancer.

There have been a substantial amount of research examining selection criteria for the ideal patient for bladder preservation, Desai says. These criteria include a smaller tumor size, the ability for surgeons to completely resect a tumor, the ability for patients to receive standard chemotherapy with concurrent radiation, and a lack of hydronephrosis, Desai explains.

When patients don’t meet some aspects of the selection criteria, it means they have a higher burden of disease, and bladder preservation may not provide as durable of control in patients with higher disease burden, Desai continues. It is important to differentiate selection criteria from eligibility, as patients not meeting the selection criteria could still be eligible for bladder preservation; rather, these patients have a higher risk of disease progression following preservation, Desai concludes.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine